Abstract
Initial therapy for low-risk patients typically involves potent antiresorptive agents such as bisphosphonates or denosumab to reduce bone resorption and fracture risk. For high-risk patients, bone anabolic agents like teriparatide or romosozumab may be preferred to stimulate bone formation, rapidly increase bone mass and enhance fracture prevention. Effective transitions between therapies are essential to sustain skeletal benefits. This review explores evidence-based strategies for sequential osteoporosis treatment.
Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use
-
Bone Density / drug effects
-
Bone Density Conservation Agents* / administration & dosage
-
Bone Density Conservation Agents* / therapeutic use
-
Denosumab / administration & dosage
-
Denosumab / therapeutic use
-
Diphosphonates / administration & dosage
-
Diphosphonates / therapeutic use
-
Drug Administration Schedule
-
Female
-
Humans
-
Osteoporosis, Postmenopausal* / drug therapy
-
Osteoporotic Fractures / prevention & control
-
Teriparatide / administration & dosage
-
Teriparatide / therapeutic use
Substances
-
Bone Density Conservation Agents
-
Denosumab
-
Diphosphonates
-
Teriparatide
-
Antibodies, Monoclonal
-
romosozumab